Toyoda Gosei Co., Ltd. (TGOSF)

Inozyme Pharma Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	151,358	118,769	146,000	105,268	109,145	134,003
Short-Term Investments	12,145	-	-	-	-	-
Cash & Short-Term Investments	163,503	118,769	146,000	105,268	109,145	134,003
Cash Growth	-6.51%	-18.65%	38.69%	-3.55%	-18.55%	4.75%
Receivables	162,724	176,384	183,871	185,640	182,595	149,249
Inventory	93,051	93,270	87,493	99,171	94,862	72,888
Other Current Assets	28,449	49,725	37,823	29,029	38,563	24,438
Total Current Assets	447,727	438,148	455,187	419,108	425,165	380,578
Property, Plant & Equipment	332,227	338,243	341,789	327,838	316,901	290,246
Long-Term Investments	75,426	110,052	112,806	95,089	93,373	78,407
Other Intangible Assets	6,286	6,408	6,190	5,240	5,154	4,571
Long-Term Deferred Tax Assets	24,357	20,184	17,371	18,021	18,706	21,349
Other Long-Term Assets	25,459	4	4	4	3	4
Total Assets	911,482	913,039	933,347	865,300	859,302	775,155
Accounts Payable	147,549	149,662	149,795	142,453	147,942	126,784
Short-Term Debt	-	1,234	4,583	12,413	37,866	15,189
Current Portion of Long-Term Debt	38,723	17,833	34,354	20,493	6,057	27,645
Current Income Taxes Payable	5,148	3,074	6,773	4,220	3,730	3,439
Other Current Liabilities	14,397	13,912	21,401	16,468	13,801	12,478
Total Current Liabilities	205,817	185,715	216,906	196,047	209,396	185,535
Long-Term Debt	74,047	90,458	99,441	130,115	129,771	109,379
Long-Term Deferred Tax Liabilities	956	925	1,699	3,211	5,304	5,015
Other Long-Term Liabilities	16,080	16,294	17,297	17,694	19,618	20,026
Total Liabilities	328,165	324,636	366,614	378,934	396,509	354,700
Common Stock	28,119	28,119	28,114	28,093	28,069	28,046
Additional Paid-In Capital	25,866	24,727	24,722	24,860	24,465	25,626
Retained Earnings	418,431	412,829	388,635	344,275	335,069	320,883
Treasury Stock	-1,569	-1,625	-1,736	-1,235	-1,233	-1,232
Comprehensive Income & Other	67,779	78,575	82,602	52,420	42,434	17,760
Total Common Equity	538,626	542,625	522,337	448,413	428,804	391,083
Minority Interest	44,691	45,778	44,396	37,953	33,989	29,372
Shareholders' Equity	583,317	588,403	566,733	486,366	462,793	420,455
Total Liabilities & Equity	911,482	913,039	933,347	865,300	859,302	775,155
Total Debt	112,770	109,525	138,378	163,021	173,694	152,213
Net Cash (Debt)	50,733	9,244	7,622	-57,753	-64,549	-18,210
Net Cash Growth	35.68%	21.28%	-	-	-	-
Net Cash Per Share	399.03	72.73	59.28	-446.04	-498.61	-140.68
Filing Date Shares Outstanding	127.24	127.24	127.03	129.49	129.46	129.45
Total Common Shares Outstanding	127.24	127.24	127.03	129.49	129.46	129.45
Working Capital	241,910	252,433	238,281	223,061	215,769	195,043
Book Value Per Share	4233.26	4264.67	4111.97	3463.00	3312.14	3021.16
Tangible Book Value	532,340	536,217	516,147	443,173	423,650	386,512
Tangible Book Value Per Share	4183.85	4214.31	4063.24	3422.54	3272.33	2985.85

Updated Jan 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.